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Studies have indicated that Alzheimer’s disease may be caused by the buildup of plaques in the 
brain, both intraneuronal and extracellular (Tanzi, 1989).  The buildup of these plaques is 
caused by the aggregation of the beta amyloid peptide that is normally found in its monomeric 
form in the human blood stream.  Development of a viable inhibitor to the aggregation of this 
peptde could result in a pharmaceutical application capable of preventing the onset of 
Alzheimer’s disease.  Several candidates for inhibitors were proposed, one of which was 
myricetin.  Myricetin is a flavonoid that occurs naturally, found in some fruits and vegetables.  To 
determine the inhibitive properties of myricetin, beta amyloid peptide was dissolved into a 
solution under conditions intended to mimic those of the human body.  After various incubation 
periods, a fluorescent indicator that would only bind with the aggregated peptide was added, 
allowing for the quantification of the degree of aggregation that occurred in the solution.   
 
